TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32891278

Group type: EXPERIMENTAL
Intervention: Peppermint essential oil inhalation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no peppermint essential oil)
Number of subjects: 60
Study: 35943609

Group type: EXPERIMENTAL
Intervention: Continuing nursing care team mode
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional telephone follow-up mode
Number of subjects: 100
Study: 33605981

Group type: EXPERIMENTAL
Intervention: Village doctor‐led multifaceted intervention
Number of subjects: 33995

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 33995
Study: 34387661

Group type: EXPERIMENTAL
Intervention: Heat (26.3°C)
Number of subjects: 14991

Group type: EXPERIMENTAL
Intervention: Cold
Number of subjects: 14991
Study: 34431972

Group type: EXPERIMENTAL
Intervention: Telepsychiatry collaborative care (TCC)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Telepsychiatry/telepsychology-enhanced referral (TER)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Phone-enhanced referral (PER)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: TCC
Number of subjects: 1004
Study: 85052396

Group type: EXPERIMENTAL
Intervention: Primary biliary cirrhosis
Number of subjects: 318

Group type: COMPARATOR
Intervention: Primary sclerosing cholangitis
Number of subjects: 318
Study: 34965774

Group type: EXPERIMENTAL
Intervention: Expanded Disability Status Scale (EDSS)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Timed 25 Foot Walk (T25FW)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Nine Hole Peg Test (NHPT)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Symbol Digit Modalities Test (SDMT)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Lesional and volumetric imaging outcomes
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: 36‐Item Short Form Health Survey (SF‐36)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Impact Scale (MSIS‐29)
Number of subjects: 889
Study: 35729038

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents (DAAs) treatment
Number of subjects: 21
Study: 34315413

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 µg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intracervical Foley catheter (FC)
Number of subjects: 120
Study: 35329051

Group type: COMPARATOR
Intervention: simple without cues
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: simple with cues
Number of subjects: 80

Group type: COMPARATOR
Intervention: complex without cues
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: complex with cues
Number of subjects: 80
Study: 32295509

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7213
Study: 34014988

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IA-thrombolysis)
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Mechanical thrombectomy alone
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Endovascular therapy (EVT)
Number of subjects: 1497
Study: 36318623

Group type: EXPERIMENTAL
Intervention: Personalized nutrition diet (n=14)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard IBS diet (n=11)
Number of subjects: 25
Study: 33502287

Group type: EXPERIMENTAL
Intervention: Self-assessments and predictions
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Formative exams
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Response rate of 20%
Number of subjects: 128

Group type: COMPARATOR
Intervention: Female students
Number of subjects: 128
Study: 35925913

Group type: EXPERIMENTAL
Intervention: Children instructed to construct the selected idea into a tangible product
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control group (children informed they had to perform another task after idea selection)
Number of subjects: 403
Study: 33398870

Group type: EXPERIMENTAL
Intervention: US-guided modified thoracolumbar interfascial plane (mTLIP) block
Number of subjects: 60
Study: 35871120

Group type: EXPERIMENTAL
Intervention: HNLP (High Nitrate Low Phenolic) - 50g of lettuce containing 530mg nitrate and 11mg phenolic compounds
Number of subjects: 19

Group type: COMPARATOR
Intervention: LNHP (Low Nitrate High Phenolic) - 50g of lettuce containing 3mg nitrate and 77mg phenolic compounds
Number of subjects: 19
Study: 34670954

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin levels in African American infants
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Fecal calprotectin levels in infants with private insurance coverage
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: S100A12 levels
Number of subjects: 124
Study: 33964383

Group type: EXPERIMENTAL
Intervention: Hip arthroscopy (CPT code 29914)
Number of subjects: 35966
Study: 33394979

Group type: EXPERIMENTAL
Intervention: Neural Therapy (NT) including local-segmental treatment (intradermal injections) on the lumbosacral region, 5M injection, pelvic plexus injection, i.v. injection (2 mL) for five sessions per week; interference field injections at the first session.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single Trigger Point Injection (TPI)
Number of subjects: 50
Study: 35380689

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 0
Study: 33499848

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (15 mg/kg in 100 mL of saline solution) administered 10 min before tourniquet release
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intra-articular TXA (15 mg/kg in 100 mL of saline solution) injected via drainage tube
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (equivalent volume of normal saline administered into the knee joint cavity and intravenously)
Number of subjects: 120
Study: 32285590

Group type: EXPERIMENTAL
Intervention: Alternative Mediterranean Diet (aMED) tertile 3
Number of subjects: 7756

Group type: EXPERIMENTAL
Intervention: Higher fish intake
Number of subjects: 7756
Study: 35986947

Group type: EXPERIMENTAL
Intervention: Methionine injection (5 g/L Met + 7.5 g/L NaCl)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Disaccharide injection (25 g/L maltose + 25 g/L sucrose + 7.5 g/L NaCl)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Methionine plus Disaccharide injection (25 g/L maltose + 25 g/L sucrose + 5 g/L Met + 7.5 g/L NaCl)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Non-injection (control group)
Number of subjects: 600
Study: 34233152

Group type: EXPERIMENTAL
Intervention: Finite Difference Method (FDM) for modeling tablet disintegration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDM
Number of subjects: 0
Study: 34469801

Group type: EXPERIMENTAL
Intervention: Unconditional incentives ($20 gift card)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditional incentives ($20 gift card)
Number of subjects: 0
Study: 33268325

Group type: EXPERIMENTAL
Intervention: High-flow nasal insufflation (HFNI) at 120 L/min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard flow oxygen insufflation at 10 L/min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-flow nasal insufflation (HFNI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard flow oxygen insufflation
Number of subjects: 40
Study: 32209645

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Insulin pumps
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Women with LGA infants
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard summary metrics
Number of subjects: 200
Study: 36110039

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 199

Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 199
Study: 35057457

Group type: EXPERIMENTAL
Intervention: 100 g prunes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 50 g prunes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study: 32604121

Group type: EXPERIMENTAL
Intervention: Lu-DOTATATE (median cumulative dose of 27 GBq, range 13.3-41.3 GBq, over 2-7 cycles) and 1250 mg/m capecitabine from days 0 to 14 of each PRRT cycle
Number of subjects: 45
Study: 35719637

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with temozolomide + irinotecan (T+I+B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-agent chemotherapy regimen (T+I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 0
Study: 33570654

Group type: EXPERIMENTAL
Intervention: Luspatercept
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study: 32560436

Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 104
Study: 35419898

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) tool
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Online tool
Number of subjects: 33

Group type: COMPARATOR
Intervention: Infographic tool (Control)
Number of subjects: 33
Study: 33755581

Group type: EXPERIMENTAL
Intervention: Poultry ownership
Number of subjects: 118

Group type: COMPARATOR
Intervention: No poultry ownership (Control)
Number of subjects: 118
Study: 34896233

Group type: EXPERIMENTAL
Intervention: Facilitators to uptake of core outcome sets (COS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Barriers to uptake of core outcome sets (COS)
Number of subjects: 13
Study: 34959951

Group type: EXPERIMENTAL
Intervention: Potassium gluconate supplementation (1000 mg/day added to a basal diet of 2300 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (basal diet of 2300 mg/day potassium)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Potato sources (1000 mg/day added to a basal diet of 2300 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Potassium gluconate supplementation
Number of subjects: 30
Study: 35030036

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg once daily and rituximab 375 mg/m2 (total of eight doses)
Number of subjects: 50
Study: 34828781

Group type: EXPERIMENTAL
Intervention: BEMPU TempWatch
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study: 35656793

Group type: EXPERIMENTAL
Intervention: Alopecia Areata Symptom Impact Scale (AASIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alopecia Areata Quality of Life Index (AA‐QLI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment with dupilumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AASIS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SALT score ≤ 20
Number of subjects: 0
Study: 32752021

Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Reference intakes
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Health Star Rating system
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Multiple traffic lights
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Warning symbol
Number of subjects: 1032
Study: 35388606

Group type: COMPARATOR
Intervention: Oral isotretinoin (0.5 mg/kg once daily for 16 weeks) + SM peeling (20% salicylic and 10% mandelic acid every four weeks for 16 weeks)
Number of subjects: 58
Study: 32623812

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (monthly for 2 years)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo treatment (monthly for 2 years)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Maintaining sufficient vitamin D levels (n = 226)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Not maintaining sufficient vitamin D levels (n = 114)
Number of subjects: 413
Study: 32168433

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP)
Number of subjects: 0
Study: 35145675

Group type: EXPERIMENTAL
Intervention: Thyroid sacrificing group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Thyroid sparing group
Number of subjects: 100
Study: 32203933

Group type: EXPERIMENTAL
Intervention: Muscle power training (PT) session
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control session without exercise
Number of subjects: 13
Study: 33386338

Group type: EXPERIMENTAL
Intervention: Enteral water‐soluble vitamin A (5000 IU per day)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Enteral water‐soluble vitamin A
Number of subjects: 188
Study: 33235285

Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 34217854

Group type: EXPERIMENTAL
Intervention: Self-supervised Non-Parametric Instance Discrimination (NPID)
Number of subjects: 4757

Group type: COMPARATOR
Intervention: Supervised-trained networks
Number of subjects: 4757

Group type: COMPARATOR
Intervention: Human ophthalmologists
Number of subjects: 4757
Study: 34036557

Group type: EXPERIMENTAL
Intervention: Random forest algorithm using 13 SNPs (ANRIL, HOTAIR, IL‐6, IL‐8)
Number of subjects: 400
Study: 34763652

Group type: EXPERIMENTAL
Intervention: Training intervention based on the transactional model, consisting of 6 training sessions.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Training intervention based on the transactional model.
Number of subjects: 116
Study: 32886566

Group type: EXPERIMENTAL
Intervention: Letter only outreach
Number of subjects: 2626

Group type: EXPERIMENTAL
Intervention: Letter and telephone call outreach
Number of subjects: 2626

Group type: EXPERIMENTAL
Intervention: Letter, text message, and telephone call outreach
Number of subjects: 2626

Group type: COMPARATOR
Intervention: Control group (no outreach)
Number of subjects: 2626
Study: 34715537

Group type: COMPARATOR
Intervention: Virtual bedside teaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-person bedside teaching
Number of subjects: 0
Study: 33313936

Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (5 full-face sessions over 2 years)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cryosurgery (lesion-directed)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy
Number of subjects: 58
Study: 34853156

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BRJ) (12.9 mmol nitrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted BRJ)
Number of subjects: 20
Study: 32195858

Group type: EXPERIMENTAL
Intervention: Surgical video
Number of subjects: 22

Group type: COMPARATOR
Intervention: Text-based materials alone
Number of subjects: 22
Study: 36444695

Group type: EXPERIMENTAL
Intervention: Advice from prognostic algorithm (PiPS-B14)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Advice from another clinician
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Advice of intermediate strength (75%)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Advice received at 50% strength
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Advice received at 90% strength
Number of subjects: 283
Study: 33037795

Group type: EXPERIMENTAL
Intervention: Osseodensification (OD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Under Drilling (UD)
Number of subjects: 30
Study: 36131630

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for 60 min before and after the procedure
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-KMC (control)
Number of subjects: 80
Study: 33485635

Group type: EXPERIMENTAL
Intervention: Genetically determined bilirubin
Number of subjects: 331002
Study: 35501091

Group type: EXPERIMENTAL
Intervention: Single-port insufflation endoscopic nipple-sparing mastectomy (SIE-NSM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional open mastectomy (C-OM)
Number of subjects: 0
Study: 33884979

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 40
Study: 36424554

Group type: EXPERIMENTAL
Intervention: Left nostril (Group L, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Right nostril (Group R, n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Left nostril (Group L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Right nostril (Group R)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 34679404

Group type: EXPERIMENTAL
Intervention: M-Pharm/ECT (pharmacotherapy plus maintenance ECT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: M-Pharm (pharmacotherapy alone)
Number of subjects: 37

Group type: COMPARATOR
Intervention: M-Pharm/ECT and M-Pharm
Number of subjects: 37
Study: 33451057

Group type: EXPERIMENTAL
Intervention: 1.6 g of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) per day (0.3 g EPA and 1.3 g DHA) in a microencapsulated powder
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 32516769

Group type: EXPERIMENTAL
Intervention: 550 ppm F dentifrice (pea size or transversal technique)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1,100 ppm F dentifrice (pea size)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 550 ppm F dentifrice (transversal technique)
Number of subjects: 18
Study: 35820739

Group type: EXPERIMENTAL
Intervention: Modular-based psychotherapy (MoBa)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 70
Study: 32694001

Group type: EXPERIMENTAL
Intervention: Home-based physical exercise (60 minutes twice a week for 24 months)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Home-based physical exercise
Number of subjects: 299
Study: 33346748

Group type: EXPERIMENTAL
Intervention: Choral Singing Intervention (CSI)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Health Education Program (HEP)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 93
Study: 34131267

Group type: EXPERIMENTAL
Intervention: EPA (3.0 g/day) for 12 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DHA (1.4 g/day) for 12 weeks
Number of subjects: 22
Study: 32856211

Group type: EXPERIMENTAL
Intervention: Immune-suppressive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 0
Study: 34849918

Group type: EXPERIMENTAL
Intervention: 1.5mg/kg of etrolizumab subcutaneously every 4 weeks (q4w)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3.0mg/kg of etrolizumab subcutaneously every 8 weeks (q8w)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both dosing regimens of etrolizumab
Number of subjects: 24
Study: 34591808

Group type: EXPERIMENTAL
Intervention: Bilateral dual TAP (BD‐TAP) block with multimodal analgesia under general anesthesia using 0.25% ropivacaine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham block using 0.9% normal saline with the same multimodal analgesia regimen
Number of subjects: 76
Study: 36468650

Group type: EXPERIMENTAL
Intervention: CBTp (Cognitive Behavioral Therapy for parasomnias)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Self-monitoring control
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CBTp
Number of subjects: 19
Study: 33360967

Group type: EXPERIMENTAL
Intervention: Combinatorial pharmacogenomic test
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Single-gene guidelines
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Combinatorial pharmacogenomic test and single-gene guidelines
Number of subjects: 1022
Study: 34111277

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 731
Study: 32503556

Group type: EXPERIMENTAL
Intervention: Misoprostol (800mcg sublingual for treatment, 600mcg oral for prophylaxis)
Number of subjects: 1884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 1884
Study: 33591003

Group type: EXPERIMENTAL
Intervention: Admission hemoglobin levels
Number of subjects: 4172
Study: 33063323

Group type: EXPERIMENTAL
Intervention: Reflectance Confocal Microscopy (RCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dermatoscopic evaluation
Number of subjects: 0
Study: 36064720

Group type: EXPERIMENTAL
Intervention: Pediatric Tuina
Number of subjects: 176

Group type: COMPARATOR
Intervention: Medilac‐Vita
Number of subjects: 176
Study: 34878933

Group type: EXPERIMENTAL
Intervention: Laser Therapy (LT) (808 nm, 100 mW, 40 sec/point, 4 J/point, intra/extraoral)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser Acupuncture (LA) (same parameters as LT, applied at six acupuncture points)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (systemic medication - ETNA®, 01 capsule, 8/8 h, 30 days)
Number of subjects: 60
Study: 34092654

Group type: EXPERIMENTAL
Intervention: PD03A 15μg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PD03A 75μg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PD03A 15μg and PD03A 75μg
Number of subjects: 36
Study: 33216013

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) group program PROTECT+, 4 sessions
Number of subjects: 54
Study: 33280041

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (600 IU/day)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Vitamin D3 supplementation (3750 IU/day)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Total 25(OH)D
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Free and bioavailable 25(OH)D
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: All vitamin D variables
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Calcium and bone turnover markers
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Calculated free and bioavailable 25(OH)D
Number of subjects: 221
Study: 32627474

Group type: EXPERIMENTAL
Intervention: Zhibitai Capsules combined with statins
Number of subjects: 1538

Group type: COMPARATOR
Intervention: Statins alone
Number of subjects: 1538
Study: 34120195

Group type: EXPERIMENTAL
Intervention: Single-bone fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both-bone fixation
Number of subjects: 50
Study: 34749008

Group type: EXPERIMENTAL
Intervention: 12-month health coach intervention combined with usual oncology care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 0
Study: 32268027

Group type: COMPARATOR
Intervention: Glucocorticoid injection
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 156